Sarepta's Gene Therapy Shows Sustained Slowing of DMD Progression in Landmark Three-Year Data
New long-term results from the pivotal EMBARK trial indicate ELEVIDYS, Sarepta's gene therapy, continues to alter the disease trajectory for boys with Duchenne muscular dystrophy, with no new safety concerns emerging over three years.